This past weekend we supported the Midwestern Vascular Surgical Society's Annual Meeting in Chicago. Thanks to the attendees who stopped by to chat with us and learn about #Barostim - a novel extravascular procedure for #heartfailure patients. #MVSS24 #vascularsurgery
CVRx | Barostim
医疗设备制造业
Minneapolis，MN 12,835 位关注者
CVRx’s Barostim is a breakthrough technology that stimulates the body’s natural baroreflex to treat heart failure
关于我们
CVRx is a commercial stage, public (NASDAQ: CVRX) medical devices company located in Minneapolis, Minnesota. The company has developed proprietary implantable technology for the treatment of high blood pressure and heart failure. Barostim? triggers carotid baroreceptors - the body’s own natural blood flow regulation system - which signals the brain to regulate cardiovascular function. Patient Stories on CVRx: The accounts and quotes of patients are genuine and documented. These stories represent a unique individual experience and does not provide any indication, guide, warranty or guarantee as to the response other people may have to CVRx technologies. Barostim is a prescriptive device. For a list of all potential benefits and risks go to www.cvrx.com/benefit-risk-analysis/
- 网站
-
https://www.cvrx.com
CVRx | Barostim的外部链接
- 所属行业
- 医疗设备制造业
- 规模
- 201-500 人
- 总部
- Minneapolis，MN
- 类型
- 上市公司
- 创立
- 2001
地点
CVRx | Barostim员工
动态
-
Out now in Journal of Cardiac Failure – a new Heart Failure Society of America Scientific Statement on device-based therapies - including #Barostim - for patients with #heartfailure. According to the authors, “Device-based therapies are becoming integral to managing HF, offering a promising avenue to address the high residual risk, overcome certain limitations of drug therapy (eg, adherence and tolerance), and effectively target some of the HF-related pathophysiological alterations that may not be amenable to pharmacological therapy.” “The persistence of NYHA class II or above symptoms following 3–6 months after initiation of pharmacological GDMT and CRT (where applicable) should result in consideration of device-based therapies for HF” Read the full article here: HFSA Scientific Statement: Update on Device Based Therapies in Heart Failure - Journal of Cardiac Failure (https://onlinejcf.com) ISI: https://barost.im/ISI
Despite #GDMTworks, your patient with HF is still symptomatic & at high risk for adverse outcomes; now what ??? There is an unmet need to address residual risk in patients with chronic heart failure. With an increasing armamentarium of HF devices, it is imperative to better understand and appropriately implement these therapies. Explore the full range of device-based therapies for #FunctionNotFailure in the latest HFSA Scientific Statement in #JCF! ? Remote monitoring ? Valvular- & structural-based therapies ? Autonomic, EP, and respiratory modulators ? Durable MCS ?? https://bit.ly/47pAL1l
-
We're happy to support the Mass General Brigham #HeartFailure & Shock Symposium this week! Stop by to learn how #Barostim can help improve quality of life for #HFrEF patients. ISI: https://barost.im/ISI
-
-
We're pleased to announce new data published in JACC Journals JACC: Heart Failure by Dr. Samuel Sears and colleagues that demonstrate durable benefits in MLWHF and EQ-5D quality of life measures in #HFrEF patients with #Barostim. “Congratulations to Dr. Samuel Sears and colleagues for their detailed description of the ways Barostim alleviates the burden of heart failure and improves patients’ quality of life. The durable functional and psychological improvements associated with Barostim are unique to this therapy and superior to medical management alone. To see quality of life results that remain this significant in long-term data are rare,” said Philip Adamson, MD, MSc, FACC, FESC, FRCP (Ed), Chief Medical Officer of CVRx. “We believe this analysis of the long-term BeAT-HF data will support the shared decision making of patients and physicians when considering Barostim therapy.” Learn more: https://barost.im/3ztor3w ISI: https://barost.im/ISI
-
-
We're looking forward to #HFSA2024 later this month! Come learn from esteemed faculty - Dr. Shelley Hall, Dr. Peter Eckman, Dr. Jacob Abraham, Dr. Michael Fong, Dr. Richa Gupta and Dr. Patrick McCann - about real world strategies for incorporating #Barostim into a comprehensive #heartfailure program. Add to calendar: barost.im/4dEAMB6
-
We're honored to partner with Dr. Lauren Grimsley and Dr. Ryan Buckley and the team at UT Medical Center on their first #Barostim implant. #heartfailure #cardiology #vascularsurgery
-
-
We're happy to support the Inova Cardiovascular Symposium this weekend! Stop by our booth to learn how #Barostim can help improve quality of life for #HFrEF patients. ISI: https://barost.im/ISI
-
-
Save the date for a lunchtime panel discussion about #Barostim at #HFSA2024. An experienced faculty will discuss patient selection, patient care pathways, and real world strategies for incorporating Barostim into a comprehensive #heartfailure program. Add to calendar: https://barost.im/4dEAMB6
-
We're proud to partner with Dr. Constantin Witt, Dr. Martin Oberhoffer, PD Dr. Mansur Duran, Dr. Alexander Petrov, PD Dr. Axel Kloppe, Chief of Cardiology, and the team at Marienhospital Gelsenkirchen on their first #Barostim implant. #heartfailure #cardiology #vascularsurgery
-
-
We’re pleased to announce two new appointments to our Board of Directors – Kevin Ballinger and Mitch Hill. "We are thrilled to welcome Kevin and Mitch to our Board of Directors," said Kevin Hykes, President and CEO of CVRx. "Their extensive experience in the medical device industry, coupled with their strong track records driving growth and innovation, will be invaluable as we continue to expand the adoption of our Barostim therapy. Kevin's deep understanding of interventional cardiology and Mitch's financial acumen in high-growth healthcare companies align perfectly with our strategic goals.” Learn more: ?https://barost.im/3ZbN53o